文献速递鼻科

呼气给药系统联合氟替卡松对鼻窦术后症状复发慢性鼻窦炎伴鼻息肉患者的疗效

Efficacy of the exhalation delivery system with fluticasone in patients with chronic rhinosinusitis with nasal polyps whose symptoms recur after sinus surgery.
PubMed 文献 · Int Forum Allergy Rhinol · 2022-06-26

本研究汇总NAVIGATE I和II两项大型对照试验数据,探索性比较内镜鼻窦手术(ESS)后症状复发患者与未手术患者对呼气给药系统联合氟替卡松(EDS-FLU)的治疗反应。结果显示两组患者均获得相似且显著的多种症状与生活质量改善,但既往ESS患者对高剂量EDS-FLU(每鼻孔两喷、每日两次)的反应仅在数值上更高、未达统计学显著,而手术初治患者无此现象。

要点

  • EDS-FLU可显著改善鼻窦术后症状复发患者的慢性鼻窦炎症状与生活质量。
  • 既往ESS患者与未手术患者对EDS-FLU的疗效相似且显著。
  • 既往ESS患者对高剂量EDS-FLU的反应仅在数值上更高,未达统计学显著。

核心结论

  • 鼻窦术后症状复发患者接受EDS-FLU治疗后,症状和生活质量获得显著改善。
  • 与未手术患者不同,既往ESS患者对高剂量EDS-FLU(每鼻孔两喷、每日两次)的反应仅在数值上更高,但未达统计学显著。

研究设计与样本

  • 汇总NAVIGATE I和II两项大型对照试验的数据进行探索性分析。
  • 比较既往ESS患者与未手术患者的慢性鼻窦炎症状、息肉分级和生活质量指标。

主要发现

  • 既往ESS组:呼气给药系统-安慰剂n=53,EDS-FLU 186 μg n=52,EDS-FLU 372 μg n=49。
  • 未手术组:呼气给药系统-安慰剂n=108,EDS-FLU 186 μg n=108,EDS-FLU 372 μg n=111。
  • 两组患者经EDS-FLU治疗后在鼻塞评分、22项鼻窦结局测试(SNOT-22)、鼻窦炎残疾指数(RSDI)、患者总体印象变化及鼻息肉分级等多个指标上均报告相似且显著的获益。
  • 在既往手术患者中,多个指标(SNOT-22、RSDI、息肉分级)对较高剂量的反应在数值上更大,但未达统计学显著;未手术患者无此现象。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sinus surgery removes inflamed tissue, restores airflow, and improves delivery of medication into surgically opened spaces. The exhalation delivery system with fluticasone (EDS-FLU; XHANCE® ) uses a novel delivery system to create closed-palate, positive-pressure, bidirectional mechanics that significantly alter the deposition of the topically acting anti-inflammatory medication. We ask whether EDS-FLU efficacy differs for patients with recurrent symptoms after sinus surgery versus patients without surgery. OBJECTIVE: We aimed to compare EDS-FLU treatment responses in patients with recurrent symptoms after endoscopic sinus surgery (ESS) and patients who have never had sinus surgery. METHODS: Data were pooled from two large, controlled trials (NAVIGATE I and II) for exploratory analyses. Chronic rhinosinusitis symptoms, polyp grade, and quality-of-life measures were compared between patients with prior ESS and those without prior ESS. RESULTS: Patients with prior ESS (exhalation delivery system-placebo [n = 53], EDS-FLU 186 μg [n = 52], and EDS-FLU 372 μg [n = 49]) and unoperated patients (exhalation delivery system-placebo [n = 108], EDS-FLU 186 μg [n = 108], and EDS-FLU 372 μg [n = 111]) treated with EDS-FLU reported similar and substantial benefits as measured by multiple symptom and quality-of-life/functioning outcomes (congestion score, 22-Item Sinonasal Outcomes Test [SNOT-22], Rhinosinusitis Disability Index [RSDI], Patient Global Impression of Change) and by nasal polyp grade. In previously operated patients, unlike surgery-naive patients, multiple outcomes (SNOT-22, RSDI, polyp grade) consistently showed numerically but not statistically greater responses to the higher dose. CONCLUSIONS: Patients with recurrent symptoms after sinus surgery who were treated with EDS-FLU demonstrated significant symptom and quality-of-life improvement. Unlike unoperated patients, patients with prior ESS had a numerically but not statistically greater response to the higher dose of EDS-FLU (two sprays per nostril twice a day).

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Ow RA, Soler ZM, Sindwani R, et al. Efficacy of the exhalation delivery system with fluticasone in patients with chronic rhinosinusitis with nasal polyps whose symptoms recur after sinus surgery. Int Forum Allergy Rhinol. 2022. PMID: 35674488. doi:10.1002/alr.23043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。